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Background: There are no evidence based guidelines for the surveillance of patients with moderate-sized (<5 cm)
thoracic aortic aneurysms (MTAA), who do not warrant surgical intervention. The purpose of this study was to
review the MTAA patient surveillance strategy used currently at the Northport Veterans Affairs Medical Center, to
assess outcomes over time and accrue data to develop guidelines to optimize MTAA patients’ follow-up.
Methods: The study group included veterans referred to the Thoracic Surgery clinic for the management of
moderate-sized (<5 cm) thoracic aortic aneurysms (MTAA) not warranting immediate surgical repair.
As a pilot study, all MTAA patients’ charts from 2005–2013 were reviewed to describe imaging practices and
evaluate patient-specific long-term outcomes. An adverse composite endpoint was defined if a patient’s aneurysm
grew substantially (≥0.5 cm/year or reached 5.5 cm) or a MTAA-related event (surgery or death) occurred.
Additionally, number of CT scans obtained during the follow up period were documented.
Results: For 110 MTAA patients, the average presenting index size was 4.45 ± 0.4 cm with average growth of
0.04 cm total (0.03 cm/year). Fourteen (13%) patients met the adverse composite endpoint, with no MTAA-related
deaths. Patients achieving the adverse composite endpoint had higher index sizes (4.81 vs. 4.40 cm, p = 0.001) and
higher average growth rates as compared to non-endpoint patients (0.16 vs. 0.01 cm, p = 0.0009). Optimizing the
negative likelihood ratio defined a new “not-at-risk” population with aneurysm index size < 4.3 cm. A shorter time
to adverse event for “at-risk” patients was found versus “not-at-risk” patients (p = 0.02). On average, there were 4.8
CT scans/patient and estimated cumulative radiation dose of 34 mSv/patient. Only one “not-at-risk” patient had
substantive MTAA growth (≥0.5 cm/year) over the 8 year follow-up period.
Conclusion and relevance: Annual imaging of MTAA “not-at-risk” patients appears unwarranted, resulting in
potentially excessive radiation exposure. Although additional research is necessary for validation, longer surveillance
imaging intervals (beyond one year) seem appropriate for MTAA patients presenting with < 4.3 cm index aneurysms.
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Thoracic aortic aneurysms account for almost 50,000
deaths annually in the United States [1]. Death is due to
rupture or dissection and is strongly linked to the size of
the aneurysm [2]. Recent Guidelines for the Diagnosis
and Management of Patients with Thoracic Aortic
Disease represent the efforts of multiple professional
societies (ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/
STS/SVM) to develop evidence based recommendations* Correspondence: Allison.McLarty@stonybrookmedicine.edu
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unless otherwise stated.for the management of all aspects of thoracic aortic dis-
ease in order to improve patient outcomes [3]. The
guidelines were prepared after rigorous and careful
review of the evidence by multiple experts in the field
representing cardiologists, radiologists, vascular sur-
geons and cardiothoracic/aortic surgeons.
Current guidelines recommend surgical intervention
for ascending thoracic aortic aneurysms when they are
5 cm in size for patients with genetic predisposition to
rupture/dissection such as the connective tissue disorder
Marfan’s syndrome, or 5.5 cm in size for non-Marfan
patients [3]. Similarly the recommendations are tol. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Demographics of the patient cohort
Risk Factor N (%)
Age (Mean, Std) 70 ± 9
Body Mass Index [BMI] (Mean, Std) 31.6 ± 6
Systolic Blood Pressure (Mean, Std) 132 ± 14
Diastolic Blood Pressure (Mean, Std) 76.3 ± 12
Hypertension 89 (81%)
Diabetes 21 (19%)
Chronic Kidney Disease [CKD] 8 (7%)
Cerebrovascular Disease [CVD] 9 (8%)
Peripheral Vascular Disease [PVD] 5 (5%)
Prior Myocardial Infarction [MI] 19 (17%)
Previous Percutaneous Coronary Intervention [PCI] 19 (17%)
History of Coronary Artery Bypass Graft [CABG] Procedure 17 (15%)
Smoking Status
Last smoked < 2 weeks of surgery 14 (13%)
Last smoked > 1 year before surgery 68 (62%)
>3 months to < 1 year before surgery 2 (1.8%)
Never Smoked 17 (15.6%)
Unknown 8 (7%)
Hyperlipidemia 65 (59%)
Use of Diuretic Medications 35 (32%)
Use of ACE or ARB Medications 52 (47%)
Use of Beta-blocker [BB] Medication 45 (41%)
Use of Lipid Lowering Agent [LLA] Medication 57 (52%)
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aneurysm is 5.5 cm for a Marfan or 6 cm for a non-
Marfan patient [2-6]. These guidelines are based on data
showing increased mortality for these patients. Thus, the
risk of rupture-related complication exceeds the risk of
surgery-related complications for this high risk patient
sub-group - rendering an operation as the safer strategy.
For moderate-size (defined as ≤ 4.9 cm) thoracic aortic
aneurysms (MTAA), however, the committee concluded
that the evidence is severely lacking to establish recom-
mendations. These MTAA patients are generally not re-
ferred for surgery- but the appropriate frequency and
mode of surveillance are unclear [3].
The computed tomography (CT) scan is currently the
most commonly used form of aortic imaging, but carries
with it the risk of ionizing radiation. Only weak (level C)
evidence suggests the use of magnetic resonance im-
aging for these patients instead of computed tomo-
graphic imaging in an effort to reduce such harmful
exposure [3]. Echocardiography is used sporadically, as
clinicians have concerns about the reliability and accur-
acy of echo-based TAA aneurysm sizes [7].
In our Thoracic Surgical Clinic we see many patients
with MTAA. Current management is guided by best
clinical judgment. There is no data to guide surveillance
of these patients. Given the scarcity of reported data on
MTAA patients, the aim of our pilot study was to evalu-
ate the natural history of a cohort of our MTAA pa-
tients, to review the surveillance strategy used, and to
report on our patients’ long-term outcomes.Methods
At the Northport VA Medical Center, Institutional
Review Board (IRB) and Research and Development
(R&D) Committee approvals were obtained prior to ini-
tiating the retrospective medical chart reviews for our
pilot study (IRB# 00408). For all MTAA patients seen
during the period from 2005 to 2013 in our VA Thoracic
Surgery Clinic, the patients’ medical records were care-
fully reviewed and data extracted related to TAA
rupture-related risk factors (for example hypertension,
cigarette smoking, see Table 1), surveillance imaging ap-
proaches used (including detailed radiologic findings by
image type), as well as patient-specific short-term and
longer-term clinical outcomes.
To ensure the accuracy of all chart abstractions per-
formed, a small set of patient records were pre-tested by
two independent data collectors (SB – research resident,
and AM – senior surgical faculty attending) After com-
paring these pre-test charts, the data collection forms
were modified to assure accuracy for all future data cap-
tured. All remaining data was collected by one person
(SB) for internal consistency.Study participants
Starting in December 2005, the records for all of Northport
VA Thoracic Surgery Clinic patients were screened for po-
tential inclusion in the study. Exclusion criteria included:
(a) coarctation of the aorta; (b) any genetic disorder (i.e.
Marfan syndrome, Ehlers-Danlos syndrome, vascular form,
Turner syndrome, Loeys-Dietz syndrome, Familial thoracic
aortic aneurysm and dissection syndrome, Inflammatory
vasculitides, Takayasu arteritis, Giant cell arteritis, and
Behçet arteritis); (c) bicuspid aortic valvular disease; or
(d) a missing index CT scan (i.e., such that the size of
the aneurysm could not be accurately ascertained at
baseline).
Primary end point
Patients were considered to have met the study’s primary
adverse composite end point if one of the following out-
comes occurred at any point in time during the follow
up: 1) the size of the aneurysm grew at least 0.5 cm/year;
2) the aneurysm grew to be at least 5.5 cm; 3) the pa-
tient was offered surgery for the aneurysm; or 4) there
was an aneurysm-related death. Due to accuracy and
ready accessibility, CT scans have traditionally been the
diagnostic test of choice to measure aneurysm size. For
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serial CT images were used to evaluate the achievement
of the primary study endpoints.
Analysis plan
A descriptive analysis of patient demographics, risk fac-
tors and CT scan data was conducted and reported as
mean +/− SD or n (%) when indicated. In order to
normalize growth measurements within each patient,
total growth per year for each patient was defined as the
sum of all growth measurements over the total time
followed (calculated in days, divided by 365). First year
growth rate was defined as the sum of all growth mea-
surements within the first 390 days over the sum of all
time measurements within the first 390 days, divided by
365. Normalized for a year period appropriately, it
should be noted that 390 days was used to capture a
greater number of patients’ first year CT aneurysm size
measurements.
A Kaplan-Meier curve documented the time from ini-
tial MTAA diagnosis to time of any adverse composite
event; plotted for all patients, as well as for patient risk
sub-groups. Univariate screening was performed to iden-
tify risk factors associated with time to the adverse com-
posite endpoint using Kaplan-Meier (for categorical
predictors) or Cox Regression (for continuous predic-
tors). Interactions between patient characteristics and
aneurysm-related risk variables were also tested. Two
methods were used to identify a categorical cut-off value
for an index size measurement that might indicate a
higher “at-risk” patient sub-population. First, a visual in-
spection of the frequency distribution of initial index
size was used to identify any natural cut-point appearing
in the data [8,9]. Then, a negative likelihood ratio (NLR)
analysis was used to validate this cut-point and identify
the lowest aneurysm index size (as the new “threshold”)
that would differentiate patient risk sub-groups related
to their potential for achieving the study’s primary, ad-
verse, composite end point [10]. Otherwise stated, a
negative likelihood ratio is the probability of a negative
test result given the presence of the disease (i.e. false
negative probability), divided by the probability of a
negative test result given the absence of disease (i.e. true
negative probability). In this case, disease equates to
meeting the study’s adverse end point criteria, and a low
NLR would indicate a low chance of an individual who
was classified as “low-risk” to meet the adverse endpoint.
Negative likelihood ratios are known for ruling condi-
tions out, and thus an appropriate measure to use when
defining a threshold for possible reduction of surveil-
lance. All calculations were performed at the p = 0.05
level using SAS©9.2 software, SAS Institute Inc., Cary
NC. To report on radiation exposure, based on the most
recent published literature, a CT scan of the chest wasestimated to provide on average 7 mSV of radiation ex-
posure per imaging session [11].
Results
A total of 156 Thoracic Surgery clinic patient records
were identified for chart review. After preliminary record
screening, 44 patients were excluded for not having ei-
ther a baseline CT scan (to establish initial aneurysm
size) or having at least one additional CT scan during
the study follow-up period. Additionally, the patients
presenting with greater than mild aortic insufficiency
(AI) were also excluded (n = 2). Thus, the total number
of patient records included in this pilot study’s medical
chart review was 110. The anatomical distribution of
these included 94 (86%) in the ascending aorta, 8 (7%) in
the ascending and arch, and 8(7%) in the descending
aorta.
The average patient age was 70 ± 9 years; 80% of the
patients were diagnosed as hypertensive (Table 1). A his-
tory of tobacco use was very common in this population,
with “never smokers” representing only 15.6% of the
population.
The average time from the index CT scan to the last
follow-up CT scan was 3.23 years (STD: 2.23, RANGE:
0.11 - 9.88). The mean presenting aneurysm index size
was 4.45 cm (STD: 0.37, RANGE: 3.8 - 5.4). During the
8 year follow-up period, there was very little aneurysm
growth observed (on average, 0.04 cm total per patient,
0.03 cm per patient per year) (Tables 2 and 3).
Fourteen patients (13%) met this pilot study’s adverse
composite endpoint. Of these patients: 7 had a growth
of at least 0.5 cm/year, 2 had a follow up scan of at least
5.5 cm, 3 had both a growth of at least 0.5 cm/year and
a follow up scan of at least 5.5 cm, and 2 were offered
surgery in addition to having growth of at least 0.5 cm/
year and a follow up scan of at least 5.5 cm. (Table 3).
During the follow-up period, there were no aneurysm-
related deaths.
In general, MTAA patients who achieved the adverse
composite endpoint had higher index size (4.81 vs.
4.40 cm, p = 0.001) and a higher growth rate per year as
compared to the “non-endpoint” patients (0.16 vs.
0.01 cm, p = 0.0009). Risk factors such as smoking, age,
or hypertension appeared very similar between these two
patient sub-groups (p > 0.2).
A Kaplan Meier curve for all patients, evaluating the
time from initial diagnosis to the time of adverse com-
posite endpoint was developed (Figure 1). Univariate
screening for risk factors predicting time to event were
calculated. The only variable to achieve significance in
the univariate time to event screening was aneurysm
index size (p = 0.002).
To further explore a potential index size threshold that
might be associated with an adverse composite endpoint
Table 2 Univariate findings for patients with and without an adverse composite endpoint





Number of Patients 110(100%) 96 (87.27%) 14 (12.73%) –
Total Years Followed (Time from First to Last CT Scan) 3.23 (2.23) 3.04 (2.19) 4.58 (2.12) 0.01
Patient Characteristics
Age (Mean, STD) 70.02 (9.46) 69.59 (9.42) 72.93 (9.59) 0.22
Proportion of Patients with Hypertension 89 (80.91%) 78 (81.25%) 11 (78.57%) 0.73
Aortic Aneurysm [AA] Measurement Description
Index Size (Mean, STD) 4.45 (0.37) 4.40 (0.33) 4.81 (0.40) 0.001
Final Size (Mean, STD) 4.49 (0.46) 4.40 (0.35) 5.17 (0.51) <0.0001
Total Average Growth (Mean, STD) 0.04 (0.29) −0.004 (0.23) 0.36 (0.34) 0.0009
Total Average Growth Per Year (Mean, STD) 0.03 (0.24) 0.01 (0.22) 0.16 (0.42) 0.017
Average First Year Growth (Mean, STD) 0.02 (0.24) 0.02 (0.20) 0.01 (0.47) 0.15
First Year Growth Rate (Mean, STD) −0.33 (3.51) 0.008 (0.34) −2.63 (9.79)
First Year Growth Rate Alternative Calculation (Mean, STD) −0.009 (0.42) −0.01 (0.32) −0.001 (0.85) 0.133
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played for the sub-groups with and without an adverse
composite endpoint (Figure 2). Based on visual inspec-
tion, a natural cut point in the data appeared to be lo-
cated around 4.3 cm. A negative likelihood ratio analysis
(NLR) was used to validate this cut point; the smallest
NLR was achieved using ≥ 4.3 cm as the threshold meas-
ure to differentiate “at-risk” versus “not-at-risk” patients
for an adverse, composite event. It should be noted that
the NLR = 0.18 generally indicates only mild to moderate
refinement in the diagnostic process; thus, this threshold
may likely be useful for clinical decision-making purposes
when combined with other relevant diagnostic test informa-
tion (i.e., patient history) and/or expert clinician judgment.
Using this novel “not-at-risk” cut-off value, time to
event was graphed (Figure 3), showing a significant
difference in time to event for those with a ≥ 4.3 cm
as compared to those with a < 4.3 cm index aneurysm
(p = 0.02). Using the index size threshold of > 4.3 cm,
moreover, there was only one “not-at-risk” patient
with an index aneurysm size under this 4.3 cm thresh-
old that achieved any study adverse endpoint. For this
specific patient, the first endpoint (aneurysm growth ≥
0.5 cm/year) was met within 120 days following ini-
tial diagnosis; but no other study adverse endpoints
(e.g., total growth threshold, TAA-related surgery, or
TAA-related death) were documented.Table 3 Detailed description of 14 individuals with an advers
Adverse event descriptions Patient
count
Criteria #1: growth of 0.5/yr
Criteria #1: Growth of 0.5/yr 12 7
Criteria #2: Any size ≥ 5.5 7 3
Criteria #3: Offered surgery 2 0To evaluate the cumulative radiation exposure, the
timing and findings for all images were compiled. For
the 110 patients, there were a total of 525 CT scans per-
formed: 434 CT scans for patients that did not achieve a
study endpoint and 91 CT scans for patients achieving
any study endpoint. On average, there were 4.8 scans for
all patients; 4.5 scans for patients with no endpoint
achieved versus 6.5 scans for patients reaching any com-
ponent of the adverse composite endpoint. Although
aneurysm size was recorded on all scans, approximately
half (n = 262/525; generally the older scans) of the his-
torical CT scans did not have radiation dosage informa-
tion recorded. As detailed radiation exposure data were
not uniformly available for all scans, an estimated 7 mSv
radiation dose per scan was used to calculate the total
cumulative radiation dose per person [11]. With an esti-
mated cumulative effective radiation dose of 34 mSv/pa-
tient, the radiation exposure to our patients was
identified to be an important risk related to our histor-
ical surveillance monitoring practices.
Discussion
Aortic aneurysms are of concern because of their poten-
tial risk of death. The likelihood of a mortal event occur-
ring has been linked historically to aneurysm size.
Elegant natural history studies from the 70s and 80s
demonstrated a significant increased incidence ofe composite endpoint





Figure 1 Kaplan Meier for all patients followed. A Kaplan Meier curve for all patients, evaluating the time from initial diagnosis to the time of
adverse composite endpoint was developed.
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aorta and 7 cm for the descending aorta. Consensus
guidelines developed in 2009 suggest that ascending aor-
tic aneurysms greater than or equal to 5.5 cm warrant
surgical repair [3]. Surgery is not recommended for an-
eurysms less than 5 cm diameter. However even with a
smaller diameter there is still a risk of complication.
Thus even for MTAA patients with an initial aneurysm
size of 4–4.9 cm, there is 5 - 10% yearly risk of rupture,
dissection or death [12]. To-date, the sub-group of these
MTAA patients at highest risk for a future adverse event
has not been well established - driving the contemporan-
eous practice for risk factor modification and close sur-
veillance. With increasing awareness of the danger of
radiation exposure however, there remains a real need to
identify an optimal surveillance interval differentially for
follow-up of “at-risk” versus “not-at risk” MTAA patient
sub-groups.Figure 2 Frequency distributions for index size measurements. Data v
patients, as well as for subgroups that met or did not meet the study endpGiven their inherent, asymptomatic nature, the true
MTAA incidence cannot be known. However in an in-
teresting study, Itani et al. reported the detection of
asymptomatic aortic aneurysms in a mass lung cancer
screening program using mobile helical computed tom-
ography units. They found 11 of 6,971 (0.16%) of
screened subjects to have aortic aneurysms [13]. Simi-
larly in our study, all of our MTAA patients presented
with asymptomatic aneurysms and were diagnosed as an
incidental finding.
Of the 110 records reviewed, only 14 (13%) met the
endpoint criteria of substantive growth or requiring sur-
gery. There were no aortic aneurysm related deaths.
Throughout our study period, the assessment and
follow-up practices at our institution were the same for
all study patients and followed current convention which
among many practitioners has been to repeat imaging
every 6 months up to 1-year; then once aneurysmisualization for initial index size showing a natural cut-point for all
oint.
Figure 3 Kaplan Meier index size value measurement ≥ 4.3 cm. Using this novel “not-at-risk” cut-off value, time to event was graphed
showing a significant difference in time to event for those with a ≥ 4.3 cm as compared to those with a < 4.3 cm index aneurysm (p = 0.02).
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thereafter.
The very low aneurysm growth rate of our MTAA pa-
tients during the follow-up period suggests that such an-
nual imaging of all patients, the unstated “standard of
care”, may be excessive and unnecessary for “lower -risk”
MTAA patient sub-groups’ as well as pose a potential
health hazard related to excessive radiation exposure
which in this study was not insignificant. Although the
exact radiation doses could not be determined (due to
missing CT radiation exposure data), there were 4.8 CT
scans per patient with an estimated mean cumulative ef-
fective radiation dose of 34 mSv per patient.
Given difficulties of comparing aneurysm sizes across
imaging modalities, the CT scan has been generally con-
sidered as the “gold standard” approach that should be
used to measure aneurysm size. As low dose CT imaging
becomes more refined, the future radiation exposure to
patients being followed for aneurysm and other intra-
thoracic pathology may decrease. Until low dose CT
scans become routine, however, alternate imaging ap-
proaches should be further explored to ensure the most
accurate, cost-effective and safe modality for MTAA pa-
tients and optimal interval of imaging needs to be
clarified.
Unfortunately, many patients are not able to undergo
alternative imaging approaches. Although MRI has less
radiation exposure, MRI procedures are currently
lengthy and expensive and the presence of a devices
such as pacemakers renders them ineligible. While
cheaper, safer, and more readily accessible, echocardiog-
raphy appears to be a less reliable approach to document
aneurysm size, as the echo findings may be (at least, in
part) operator dependent [7]. Moreover, aneurysms ofthe arch and descending thoracic aorta cannot be accur-
ately followed using an echo-based surveillance strategy,
making the use of echo as the sole method of measure-
ment of aortic size controversial. Hence, only CT scan
findings were used for purposes of this pilot study to as-
sess index and changes over time in aneurysm size.
Previous studies have established guidelines for when
to operate on large aneurysms; defining a “hinge point”
where the percentage point increase of complications is
significantly amplified after a certain aortic diameter is
exceeded. In our study, we used the negative likelihood
ratio (as a diagnostic test performance metric) to identify
a similar “hinge point” where MTAA patients were more
likely to achieve the study endpoint based on their index
aneurysm size. As the likelihood of an adverse event in-
creases above the threshold of 4.3 cm, more frequent
surveillance of “at-risk” patients might be warranted.
Conversely “not-at-risk” patients may not need to be
subjected to frequent imaging leading to significant
amounts of radiation with unclear benefit.
This study is retrospective in nature, and therefore has
several inherent limitations. While the total patient
population size is low, it is comparable to other pub-
lished studies reporting a unique patient sub-group.
Measurements of the aortic size were derived from the
radiology report and not directly measured from the
scan. However since many surgeons depend on radi-
ology reports and reported sizes for comparisons this
data extraction method may be clinically relevant. Aortic
diameter was not normalized to patients’ body-surface
area in this analysis as current guidelines employ diam-
eter in their recommendations. In future studies how-
ever, we think it would be meaningful to also analyze
normalized aortic size to clarify the potential limitation
McLarty et al. Journal of Cardiothoracic Surgery  (2015) 10:17 Page 7 of 7of aortic diameter alone as predictor of risk. Finally, as
radiation doses associated with the images performed at
our VA Medical Center were not consistently or uni-
formly recorded, a recently published average CT radi-
ation dosage per scan was used to estimate our patients’
average cumulative radiation exposure [11].
Conclusion
As a very novel approach, the 4.3 cm index TAA thresh-
old will require external validation, application, and
evaluation in a different MTAA patient population.
However, this study’s threshold has the potential to aid
clinicians in identifying “at-risk” versus “not-at-risk” pa-
tient subgroups with MTAA. This is in contrast to the
current strategy which is based on best clinical judg-
ment. A data driven patient care plan will guide an opti-
mal surveillance strategy for these patients and spare
many the risk and exposure of unnecessary CT imaging.
Abbreviation
MTAA: Moderate thoracic aortic aneurysms.
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